Advos

Regentis Biomaterials announced plans to start surgeon training in Europe for its CE Mark-approved knee cartilage treatment GelrinC, advancing its commercial rollout.

Redwood AI Corp. is developing a proprietary AI platform for drug discovery, synthesis planning, and chemical analysis, targeting pharmaceutical, defense, public safety, and industrial markets through research collaborations and government-supported initiatives.

Quantum BioPharma announced the completion of Phase 1 clinical studies for LUCID-MS, a therapy targeting myelin repair in multiple sclerosis, and submitted an Investigational New Drug application to the FDA.

CNS Pharmaceuticals discusses its oversubscribed $22.5 million financing and strategic reset, indicating strong institutional investor confidence and a strengthened balance sheet for pursuing transformative opportunities.

Small businesses in high-growth markets like Miami are preparing for increased demand from major events such as Formula 1 and the FIFA World Cup, but face challenges securing working capital quickly to seize opportunities.

The Deady Group, a Boston-based independent technology advisory firm, refocuses on technology procurement, utility procurement, and recurring spend management, potentially helping regulated and innovation-driven organizations reduce recurring spend by 15% to 30%.

Foresight Autonomous Holdings has entered into a definitive agreement with VisionWave Holdings for a strategic equity investment of up to $17.5 million, aiming to combine their sensing technologies to develop advanced AI-powered solutions for defense and security applications.

Xeriant's NexBoard fire-resistant construction panel attains the top Class A fire rating in ASTM E84 testing, expected to accelerate commercialization and convert a backlog of potential customers.

Gold prices have stalled after record highs, with monetary policy now exerting a disproportionate impact on the trajectory of the precious metal, prompting investors to recalibrate their strategies.

Redwood AI Corp. is emerging as a specialized AI platform serving government, defense, and healthcare markets, with partnerships in Canada and a proposed quantum cybersecurity acquisition.

MAX Power Mining Corp. sells its Willcox Playa Lithium Project in Arizona to Homeland Critical Minerals Corp. for 11 million shares, sharpening its focus on natural hydrogen exploration in Saskatchewan.

MAX Power Mining Corp. divests its Willcox Playa Lithium Project to Homeland Critical Minerals Corp. for $1.1 million in shares, sharpening its focus on natural hydrogen exploration in Saskatchewan.

TransCode Therapeutics will host its first R&D webcast on June 18, 2026, to discuss its Phase 2a trial of TTX-MC138 in colorectal cancer and broader pipeline updates.

Safe Pro Group Inc. has fulfilled a $743,000 U.S. Army order for its AI-powered Threat Analysis Kit, integrating drones and edge computing to rapidly identify explosive threats and generate battlefield maps.

Technology companies like Microsoft are increasingly adopting microgrids to ensure reliable power for AI data centers, addressing grid strain and energy cost concerns.

Oncotelic Therapeutics will showcase its PDAOAI platform, built on Qdrant infrastructure, which accelerated two drug candidates from concept to IND filings in under two years, demonstrating a major reduction in time and cost for pharmaceutical development.

Tonix Pharmaceuticals announced a coverage agreement with a second major group purchasing organization, expanding TONMYA's commercial access to 52 million lives, representing about 29% of U.S. commercially insured individuals.

Regentis Biomaterials plans to begin European surgeon training in Q3 2026 for its CE Mark-approved GelrinC knee cartilage implant, advancing commercialization.

Logan Freeman of Midwest CRE Advisors shares a repeatable process for evaluating industrial buildings for edge data center conversion, focusing on electrical infrastructure, floor load, cooling, and prior use, which can compress deployment timelines and reduce costs.

Daniel Kaufman, founder of Kaufman & Company, is recalibrating his real estate development strategy toward simpler, mission-aligned projects he can explain in two sentences, arguing that smaller deals can yield better returns with less risk.